The effect of cilostazol on thrombosis and atherosclerosis in DM patients
| Project/Area Number |
16K20002
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
Miyai Masafumi 岐阜大学, 医学部附属病院, 医員 (60613502)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | シロスタゾール / 糖尿病 / 血小板活性化 / 血小板凝集能検査 / 動脈硬化 |
|---|
| Outline of Final Research Achievements |
In the present study, we conducted an investigation into the effect of cilostazol on the phosphorylation of heat shock protein 27 (HSP27) and the release of platelet factor 4 and soluble CD 40ligand from collagen-activated platelets in type 2 diabetes mellitus (DM) patients.
It was demonstrated that the rate of platelet aggregation was reduced up to 1.0 micro M, and the levels of phosphorylated-HSP27 (Ser-78 and Ser-82) were also attenuated after cilostazol adminstration.The released platelet factor 4 and soluble CD 40ligand levels from collagen-stimulated platelets were reduced by administration of cilostazol. These results strongly suggest that cilostazol inhibit collagen-induced activation of platelets through attenuation of phosphorylated-HSP27 and release of platelet factor 4 and soluble CD 40ligand in type 2 DM patients.
|
Report
(3 results)
Research Products
(3 results)
